VIDEO: Takeaways from AHA 2022 with B. Hadley Wilson, MD, FACC
CHICAGO — In this Healio exclusive, B. Hadley Wilson, MD, FACC, provides his perspective on several late-breaking clinical trials presented at the American Heart Association Scientific Sessions.
Wilson discusses results of OPTION, a randomized, open-label, noninferiority trial that evaluated efficacy and safety of indobufen compared with aspirin after coronary drug-eluting stent implantation; BRIGHT-4, a randomized trial that assessed high-dose bivalirudin infusion after percutaneous coronary intervention compared with heparin in STEMI; ECMO-CS, a randomized trial that looked at early extracorporeal membrane oxygenation compared with a conservative strategy for the treatment of cardiogenic shock; and ISCHEMIA-EXTENDed, an extended follow-up study of 4,825 patients from the ISCHEMIA trial.
Wilson is executive vice chair of Atrium Health’s Sanger Heart & Vascular Institute, clinical professor of medicine at UNC School of Medicine and vice president of the American College of Cardiology.
Watch the video for more.
Collapse
Healio Interviews